Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2016

View Archived Issues

Departament of Defense awards Capricor Therapeutics grant for the development of CAP-2003

Redx compounds effective against drug-resistant strains of Gram-negative bacteria

Sanofi Pasteur announces BARDA phase II funding for Zika vaccine work

Kite Pharma reports topline data from ZUMA-1 study of KTE-C19 in DLBCL

Therapeutic RNA splicing modulation impairs leukemia stem cell maintenance in secondary AML

Pilot study finds significant hair regrowth with ruxolitinib in alopecia areata

LTbetaR is a potential novel immunotherapeutic target to boost T cell recovery

Asterias Biotherapeutics doses first AIS-B patient in SCiSTAR trial

Pharmakea patents LOX2 inhibitors

Hoffmann-La Roche discloses TLR8 agonists

Genentech and Hoffmann-La Roche describe DLK inhibitors

CLARION study of Kyprolis in newly diagnosed multiple myeloma does not meet primary endpoint

University of California develops anti-alphavbeta1 integrin inhibitors

Bristol-Myers Squibb to collaborate with Nectar Therapeutics for cancer combination treatment

Shuttle Pharmaceuticals presents HDAC inhibitors and erine-protein kinase ATM activators

FDA grants pediatric disease designation to Summit's ezutromid

MFMER reports NADH-ubiquinone oxidoreductase inhibitors

AcelRx initiates phase III study of Zalviso for moderate to severe postoperative pain

Lumicef set for first global launch in Japan this month

Beyondspring Pharmaceuticals enrolls first patient in phase Ib/II trial of plinabulin

GPR44 antagonism improves islet survival in a diabetes model

FDA approves Janssen Biotech's Stelara for Crohn's disease

[18F]T-807 imaging may be able to identify chronic traumatic encephalopathy in living people

Aerpio Therapeutics doses first subject in phase Ia trial of AKB-4924

Evotec and C4X Discovery establish new multitarget collaboration

Enrollment opens in phase III VICTORIA study of vericiguat for HFrEF

Shire terminates collaboration agreement with Momenta Pharmaceuticals for M-923

Coherus Biosciences regains rights for CHS-0214 from Shire